This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Olaparib is an anticancer medicine referred to as the Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor. It was approved for its medical use on 19th December 2014.

Mechanism of Action of undefined

Olaparib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a PARP inhibitor. PARP enzymes facilitate multiple DNA repair pathways and these repair mechanisms lead to the development of cancer cells. These enzymes specifically target cells with mutations in BRCA genes. Olaparib works by inhibiting PARP enzymes blocks repair of single stranded DNA, and ultimately hinders the growth and development of cancer cells. Olaparib is prescribed alone or in combination with other anticancer drugs like bevacizumab.

Uses of undefined

Olaparib Tablet has been developed as a maintenance therapy to treat adult patients with cancer in the ovaries, fallopian tube, peritoneum, pancreas, prostate due to BRCA mutation and have completely or partially responded to platinum-based chemotherapy.

undefined Drug administaration and Dosage available

The recommended dose of Olaparib Tablet is 300mg twice a day with or without food. Olaparib Tablet is available in the doses of 100mg and 150mg and the strength varies according to the patient’s health condition. In patients with kidney impairment, the recommended dose is 200mg twice a day.

Warnings, Precautions and Side Effects of undefined


Contact your doctor right away if you experience breathlessness, chest pain, rapid heart rate, fever, cough or wheezing. Your healthcare provider will conduct blood tests before and every month during Olaparib treatment as this medicine could reduce the counts of RBC, WBC, and platelets. Tell your healthcare provider before starting treatment with Olaparib if you have been diagnosed with problems in your lungs, liver, heart or kidneys.


 Olaparib is not recommended during pregnancy as it might harm the unborn baby and lead to miscarriage. Hence, it is advisable to do a pregnancy test before starting this treatment for women of childbearing age. Ideally, it is better to continue birth control methods for a minimum of 6 months after completion of the treatment. Avoid breastfeeding your baby while you are on the treatment as it is not known whether Olaparib passes into the breast milk.

Side Effects

The common side effects that are likely to occur while you are on the treatment with Olaparib Tablet are nausea, vomiting, stomach ache, diarrhea, breathing difficulty, constipation, tiredness, indigestion, upper respiratory tract infection, urinary tract infection, dizziness, low levels of RBC, WBC and platelets in blood, and decreased appetite. If you experience unusual bleeding, bruising, rapid heartbeat, or swelling of the face and eyes, report to your doctor immediately.

Word Of Advice

Olaparib can reduce blood cell counts, so it is advisable to be prompt on blood check-ups. Avoid direct exposure to sunlight during this therapy and always apply sunscreen above SPF 50 before stepping out. Do not stop taking Olaparib without consulting your healthcare provider.

Frequently Asked Question


  1. Sebastiaan C. Goulooze et al, Olaparib, Br J Clin Pharmaco, 81:1, 171-173,
  2. AstraZeneca, US Food & Drug Administration, [Revised on Aug 2022] [Accessed on 9th Sep 2022],


The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.